Clinical trials: Diabetes Mellitus Type II
Healthy, Type 2 Diabetes Mellitus (T2D)
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants.
- Trial name
- NCT06869018
- Testing
- LY3549492
- Where
- 4 sites in Japan
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Primary Objective: To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (HbA1c) reduction at Week 26 in participants with Type 2 diabetes who have inadequate glycemic…
- Trial name
- SOTA-CKD4 (NCT03242018)
- Testing
- Sotagliflozin
- Where
- 106 sites in United States, Argentina and 13 more
- Volunteers
- 277 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 2, Impaired Renal Function
Dapagliflozin Treatment in Type 2 Diabetes
Open label, mechanistic, single-arm study to evaluate the natriuretic effect of 2 weeks dapagliflozin treatment in T2DM patients with impaired renal function.
- Trial name
- NCT04620590
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- 2 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Emerald Clinical Inc.
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00184613
- Testing
- pump, insulin glargine, insulin aspart
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Evaluation of SCOUT DS Device in the Diagnosis of Diabetes Mellitus
The primary objective is to identify compare SCOUT DS to random capillary glucose for identification of at-risk subjects with dysglycemia defined by hemoglobin A1C ≥ 6.0%.
- Trial name
- NCT01572415
- Where
- Greece
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- VeraLight, Inc.
Type 2 Diabetes Mellitus
MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)
A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00532935
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 517 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD
A study to evaluate the PK and PD of oral IN-105 (Insulin Tregopil) w.r.t. time of dosing prior to meal, duration between meals and type of meal .
- Trial name
- NCT03392961
- Testing
- IN-105 (Insulin Tregopil)
- Volunteers
- 51 people
- Sponsor
- Biocon Limited
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756
This trial is conducted in Asia. The aim of the trial is to compare the effect on glycaemic control of biphasic insulin aspart 30 twice daily with two different dosage split regimens for Chinese subjects with type 2 diabetes who…
- Trial name
- NCT01278160
- Testing
- biphasic insulin aspart 30, metformin
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes
Data Acquisition Study in Inadequately Balanced Patients With Type 2 Diabetes Mellitus
The aim of this study is to collect continuous glucose monitoring (CGM) data, coupled with physical activity and everyday day life data.
- Trial name
- NCT04155996
- Testing
- data collection
- Where
- France
- Volunteers
- 10 people
- Sponsor
- ValoTec
Diabetes Mellitus, Type 2, Diabetes Mellitus
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes
The purpose of this study is to investigate the effectiveness and safety of 12 weeks of treatment with R256918 in patients with Type 2 Diabetes Mellitus who are taking metformin.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Endocrine System Diseases, Nutritional and Metabolic Diseases
- Trial name
- NCT00672386
- Testing
- JNJ16269110, Metformin, Dietary Counseling
- Where
- 62 sites in Belgium, Denmark and 9 more
- Volunteers
- 352 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
The purpose of this study was to compare the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, United States Pharmacopeia (USP) (referred to as TCA IR in the protocol) on blood glucose (BG) in patients with…
- Trial name
- NCT02762370
- Testing
- FX006 32 mg, TCA IR 40 mg
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Type 2 Diabetes Mellitus
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
This is a phase I, open-label, fixed-sequence study in healthy Chinese subjects, performed at a single study centre. Cohort A will assess the Pharmacokinetic (PK) profile of rongliflozin when administered alone and the…
- Trial name
- NCT05497674
- Testing
- Rongliflozin, Rifampin, Probenecid
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Diabetes Mellitus, Type 2
A Study of LY2405319 in Participants With Type 2 Diabetes
The main purpose of this study was to evaluate the safety and tolerability of LY2405319. It was given as a daily injection under the skin to participants with type 2 diabetes mellitus (T2DM) for 28 days.
- Trial name
- NCT01869959
- Testing
- LY2405319
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects
KDT501 is an orally administered product designed to help control impaired glucose and insulin regulation in patients with insulin resistance.
- Trial name
- NCT02444910
- Testing
- KDT501
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- KinDex Pharmaceuticals, Inc.
Healthy
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
The purpose of this study is to assess the bioequivalence (similarity of the drug amount in blood among the formulations) of the fixed dose combination (two components combined in one tablet) of canagliflozin and metformin…
- Trial name
- NCT02077803
- Testing
- Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes.
- Trial name
- FOCUS (NCT03811561)
- Testing
- Semaglutide
- Where
- 230 sites in United States, Brazil and 17 more
- Volunteers
- 1,500 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus.
- Trial name
- NCT01703286
- Testing
- Linagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System
A multi-center, single-arm, open-label study to evaluate the safety and effectiveness of the EndoBarrier Gastrointestinal Liner System liner on glycemic control in control subjects from study #09-1 who are not treatment failures…
- Trial name
- OLE (NCT02293720)
- Testing
- EndoBarrier
- Sponsor
- Morphic Medical Inc.
Diabetes Mellitus, Type 2
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
In this study, participants will receive semaglutide and NNC0480-0389 together at the same time. Semaglutide is a medicine that can already be prescribed, whereas NNC0480-0389 is a new potential medicine.
- Trial name
- NCT05046873
- Testing
- Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL, Semaglutide 1.34 mg/mL, NNC0480-0389 A 10 mg/mL
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus
This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data of biphasic insulin aspart (NovoMix® 30) in type 2 diabetes under normal clinical practice conditions.
- Trial name
- NCT01542060
- Testing
- biphasic insulin aspart 30
- Where
- Jordan
- Volunteers
- 298 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.